PMID- 21393490
OWN - NLM
STAT- MEDLINE
DCOM- 20110901
LR  - 20211020
IS  - 1555-905X (Electronic)
IS  - 1555-9041 (Print)
IS  - 1555-9041 (Linking)
VI  - 6
IP  - 5
DP  - 2011 May
TI  - Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous 
      ambulatory peritoneal dialysis.
PG  - 1081-8
LID - 10.2215/CJN.08510910 [doi]
AB  - BACKGROUND AND OBJECTIVES: This study sought to (1) characterize the 
      pharmacokinetic (PK) profile of intravenous (i.v.) daptomycin among patients 
      receiving continuous ambulatory peritoneal dialysis (CAPD); (2) identify optimal 
      i.v. CAPD dosing schemes; and (3) determine extent of daptomycin penetration into 
      the peritoneal space after i.v. administration. DESIGN, SETTING, PARTICIPANTS, & 
      MEASUREMENTS: A PK study was conducted among eight CAPD patients. Population PK 
      modeling and Monte Carlo simulation (MCS) were used to identify CAPD dosing 
      schemes providing efficacy and toxicity plasma profiles comparable with those 
      obtained from MCS using the daptomycin population PK model derived from patients 
      in the Staphylococcus aureus bacteremia-infective endocarditis (SAB-IE) study. 
      The primary efficacy exposure target was the area under the curve (AUC). For 
      toxicity, the goal was to identify CAPD dosing schemes that minimized plasma 
      trough concentrations in excess of 24.3 mg/L. Finally, peritoneal cavity 
      penetration was determined. RESULTS: Administration of i.v. daptomycin 4 or 6 
      mg/kg, depending on indication, every 48 h was identified as the optimal CAPD 
      dosing scheme. This regimen provided cumulative (AUC(0-48)) and daily partitioned 
      (AUC(0-24 h) and AUC(24-48 h)) plasma AUC values similar to the SAB-IE or 
      "typical patient" simulations. In addition, the proportion of patients likely to 
      experience an elevated trough concentration in excess of 24.3 mg/L was similar 
      between every 48 h CAPD dosing and the referent group. Penetration into the 
      peritoneal cavity was 6% of plasma. CONCLUSIONS: Daptomycin 4 or 6 mg/kg, on the 
      basis of indication, i.v. every 48 h was found to be the optimal i.v. CAPD dosing 
      scheme.
CI  - Copyright (c) 2011 by the American Society of Nephrology
FAU - Cardone, Katie E
AU  - Cardone KE
AD  - Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, 
      NY 12208, USA.
FAU - Lodise, Thomas P
AU  - Lodise TP
FAU - Patel, Nimish
AU  - Patel N
FAU - Hoy, Christopher D
AU  - Hoy CD
FAU - Meola, Shari
AU  - Meola S
FAU - Manley, Harold J
AU  - Manley HJ
FAU - Drusano, George L
AU  - Drusano GL
FAU - Grabe, Darren W
AU  - Grabe DW
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110310
PL  - United States
TA  - Clin J Am Soc Nephrol
JT  - Clinical journal of the American Society of Nephrology : CJASN
JID - 101271570
RN  - 0 (Anti-Bacterial Agents)
RN  - NWQ5N31VKK (Daptomycin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Bacterial Agents/administration & dosage/blood/pharmacokinetics
MH  - Bacteremia/*prevention & control
MH  - Daptomycin/*administration & dosage/blood/*pharmacokinetics
MH  - Dose-Response Relationship, Drug
MH  - Endocarditis, Bacterial/prevention & control
MH  - Female
MH  - Humans
MH  - Infusions, Intravenous
MH  - Kidney Failure, Chronic/*therapy
MH  - Male
MH  - Methicillin-Resistant Staphylococcus aureus
MH  - Middle Aged
MH  - Models, Biological
MH  - Monte Carlo Method
MH  - Peritoneal Cavity
MH  - Peritoneal Dialysis, Continuous Ambulatory/*methods
MH  - Staphylococcal Infections/prevention & control
PMC - PMC3087774
EDAT- 2011/03/12 06:00
MHDA- 2011/09/02 06:00
PMCR- 2012/05/01
CRDT- 2011/03/12 06:00
PHST- 2011/03/12 06:00 [entrez]
PHST- 2011/03/12 06:00 [pubmed]
PHST- 2011/09/02 06:00 [medline]
PHST- 2012/05/01 00:00 [pmc-release]
AID - CJN.08510910 [pii]
AID - 08510910 [pii]
AID - 10.2215/CJN.08510910 [doi]
PST - ppublish
SO  - Clin J Am Soc Nephrol. 2011 May;6(5):1081-8. doi: 10.2215/CJN.08510910. Epub 2011 
      Mar 10.